• |
  • |
  • |
  • |
Donate

Product

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel?) in healthy young women administered twice daily for 14 days

Center:
Fiscal Year:
2011
Contact Information:
Product Description:
Keyword(s):
Product/Publication Type(s):
Peer-reviewed publications in scholarly journals Published/In Press
Target Audience:
Professionals, Policymakers, Students
Alternative Format:
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A